Impact of cognitive task on the posture of elderly subjects with Alzheimer's disease compared to healthy elderly subjects

2006 ◽  
Vol 21 (2) ◽  
pp. 236-241 ◽  
Author(s):  
Patrick Manckoundia ◽  
Pierre Pfitzenmeyer ◽  
Philippe d'Athis ◽  
Véronique Dubost ◽  
France Mourey
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Task ◽  
Elderly Subjects ◽  
Healthy Elderly ◽  
Healthy Elderly Subjects

scholarly journals Lexical Retrieval or Semantic Knowledge Which One Causes Naming Errors in Patients with Mild and Moderate Alzheimer’s Disease

2017 ◽  
Vol 7 (3) ◽  
pp. 419-429 ◽  
Author(s):  
Masoome Salehi ◽  
Mohsen Reisi ◽  
Leila Ghasisin
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Healthy Subjects ◽  
Conceptual Knowledge ◽  
Semantic Knowledge ◽  
Elderly Subjects ◽  
Lexical Retrieval ◽  
Healthy Elderly ◽  
Written Word ◽  
Healthy Elderly Subjects

Background: The purpose of the study was to analyze naming errors in patients with Alz­heimer’s disease in comparison to healthy subjects and determine the underlying cause of naming errors in these patients. Method: In this study, we included 35 healthy elderly subjects, 23 patients with mild Alzheimer’s disease, and 23 with moderate Alzheimer’s disease. Forty-five images were used to determine the type of naming errors, and to identify the underlying cause of errors, matching an image with a written word was used. Results: Patients with Alz­heimer’s disease had more naming errors compared with the group of healthy elderly, and patients with moderate Alzheimer’s disease showed a slower reaction in matching an image with a written word. Conclusion: Anomia in the initial phase of Alzheimer’s disease is due to problems in lexical retrieval; however, as the disease advances, in addition to lexical retrieval problems, conceptual knowledge causes naming problems.

Implications of the Study Population in the Early Evaluation of Anticholinesterase Inhibitors for Alzheimer's Disease

1992 ◽  
Vol 26 (9) ◽  
pp. 1118-1122 ◽  
Author(s):  
Neal R. Cutler ◽  
John J. Sramek ◽  
Michael F. Murphy ◽  
Ralph J. Nash
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Multiple Dose ◽  
Elderly Subjects ◽  
Elderly Men ◽  
Double Blind ◽  
Healthy Elderly ◽  
Multiple Dose Study ◽  
Dose Study ◽  
Healthy Elderly Subjects

OBJECTIVE: Velnacrine testing for tolerance and safety in both normal elderly subjects and patients with Alzheimer's disease (AD) is reviewed to illustrate the importance of Phase I trials in the target group as more predictive of safety and tolerance for subsequent multicenter trials than those conducted in healthy elderly subjects. DESIGN: Both a single-dose and a randomized, double-blind, placebo-controlled, ascending, multiple-dose study were performed with healthy, elderly men. In the multiple-dose study, the subjects were randomized to four groups of 14, with 10 subjects receiving velnacrine and 4 receiving placebo. The doses were velnacrine 25 (group 1), 50 (group 2), and 100 mg (group 3), respectively, administered twice daily; group 4 received 100 mg three times daily for 28 days. Blood and urine were collected serially for the pharmacokinetic assessment. With AD patients, 24 subjects were randomly assigned to receive either placebo or velnacrine for 10 days in a double-blind, sequential escalation study in a hospital setting. There were three groups of 8 subjects. Six patients in each group received velnacrine and 2 placebo. The three groups received respective dosages of 450, 300, and 225 mg/d three times daily. Adverse events were closely monitored and recorded. PATIENTS/PARTICIPANTS: The multiple-dose test in healthy elderly men included 56 men, aged 60–74 years. Rigorous screening for any potential complications that could affect absorption, distribution, metabolism, or excretion preceded patient entry in the AD patient study. Patients with a history of major psychiatric, neurologic, and cardiovascular disorders were excluded. The patients ranged in age from 56 to 89 years, and were equally distributed between gender. INTERVENTION: Velnacrine was administered in various doses. MAIN OUTCOME MEASURES: We emphasize the extreme adverse effects encountered in the AD patient group compared with the healthy group. Plasma concentrations of velnacrine over time in both groups are given, as well as the drug's half-life and excretion rates. RESULTS: The tolerable dosage predicted by studies performed in healthy elderly subjects was 300 mg/d. This dosage was not tolerable among the AD patients. A dosage as high as 450 mg/d resulted in a tonic seizure in one patient. The predicted dosage of 300 mg/d produced an adverse effect profile in AD patients that included dizziness, nausea and/or vomiting, headaches, and severe diarrhea. AD patients tolerated a dosage of 225 mg/d. CONCLUSIONS: A velnacrine dosage of 300 mg/d that was tolerated in healthy elderly subjects was not tolerated by AD patients.

scholarly journals P1-189: Comparison of brazilian portuguese lexical production of Alzheimer's disease patients and healthy elderly subjects

2009 ◽  
Vol 5 (4S_Part_8) ◽  
pp. P232-P232
Author(s):  
Renné P. Alegria ◽  
Tibor R. Perroco ◽  
Rita de Cássia G. Marques ◽  
Maria Inês Nogueira ◽  
Cássio M. C. Bottino
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Brazilian Portuguese ◽  
Elderly Subjects ◽  
Healthy Elderly ◽  
Healthy Elderly Subjects
Sign in / Sign up

Export Citation Format

Share Document